Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly receives $150 million for Cialis

This article was originally published in Scrip

Executive Summary

Lilly will receive $150 million for licensing the commercialisation rights of Cialis (tadalafil) for pulmonary arterial hypertension to a biotechnology company, in which it is also buying a stake. United Therapeutics will pay the money up front to exclusively commercialise the phosphodiesterase V inhibitor for PAH in the US. Cialis, currently indicated for erectile dysfunction, is under regulatory review for the PAH indication in the US, Canada, Mexico, Japan and the EU. Pfizer already widely markets its similar erectile dysfunction drug Viagra (sildenafil) as Revatio for PAH. Lilly will manufacture and supply tadalafil to United Therapeutics and will retain global authority over the regulatory affairs, development, IP and manufacturing of tadalafil for all potential indications. It is buying $150 million of common United Therapeutics stock. The deal will strengthen United Therapeutics' strong portfolio of cardiovascular treatments. It already markets subcutaneous and intravenous Remodulin (treprostinil) for PAH. It has announced that the Freedom-C Phase III trial of oral trepsotinil missed its primary endpoint. Its share price fell to $58.62 at the end of trading, down from $90.52 on November 14th.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031738

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel